February 2023 FDA Recall Drug by Leadiant Biosciences, Inc.
D-0327-2023 - Lack of assurance of sterility

This Class II drug recall was voluntarily initiated by Leadiant Biosciences, Inc. on February 3, 2023 for the product Drug. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0327-2023

Reason for Recall
Lack of assurance of sterility: Medial fill with presence of Cupriavidus pauculus.
Initiated
02-03-2023
Reported
02-22-2023
Quantity
31,879 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Leadiant Biosciences, Inc.
Abelcet (Amphotericin B Lipid Complex) Injection, 5 mg/mL, 100 mg vial, Rx only, Manufactured by Exelead, Inc., Indianapolis, IN 46268; Distributed by Leadiant Biosciences, Inc., Gaithersburg, MD 20878, NDC 57665-101-41

Batch or Lot Expiration Information

Lot# : 1203A, Exp. 5/11/2024